Aktie ZALICUS INC
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Zalicus Inc Nasdaq

Aktien

US98887C2044

Schlusskurs Nasdaq
Andere Börsenplätze
- USD - Intraday Chart für Zalicus Inc
2016 Transcript : EPIRUS Biopharmaceuticals, Inc., Q4 2015 Earnings Call, Mar 15, 2016
2015 Transcript : EPIRUS Biopharmaceuticals, Inc., Q3 2015 Earnings Call, Nov 16, 2015

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.
Praxis Precision Medicines, Inc. completed the acquisition of Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q).
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.
Praxis Precision Medicines, Inc. agreed to acquire Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q) for $1 million.
Notice of Intent of Asset Sale Filed by EPIRUS Biopharmaceuticals, Inc.
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.
EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from S&P TMI Index
EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from NASDAQ Composite Index
EPIRUS Biopharmaceuticals, Inc. Announces Management Resignations
EPIRUS Biopharmaceuticals, Inc. Filed for Bankruptcy
EPIRUS Biopharmaceuticals, Inc. Announces Executive Termination
Polpharma S.A. completed the acquisition of EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc..
Polpharma S.A. entered into a binding term sheet to acquire EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc. for $3.5 million.
EPIRUS Biopharmaceuticals, Inc. Announces Executive Changes
EPIRUS Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
EPIRUS Biopharmaceuticals, Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2015
EPIRUS Biopharmaceuticals, Inc. Initiates Pivotal Global Phase 3 Clinical Study for BOW015 (Infliximab Biosimilar)
EPIRUS Biopharmaceuticals, Inc Provides Clinical Program Update on BOW015
EPIRUS Biopharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015
EPIRUS Biopharmaceuticals, Inc. Appoints Vincent E. Aurentz as Chief Business Officer
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A117U3 Aktie
  4. Aktie
  5. Nachrichten Zalicus Inc
  6. Andere Sprachen